Clearside Biomedical Announces Multiple Oral Presentations to be Given at the American Society of Retinal Specialists (ASRS) Annual Meeting
July 18, 2019 07:05 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., July 18, 2019 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for...
Clearside Biomedical Announces License Agreement with Aura Biosciences for Suprachoroidal Space Microinjector™ Designed to Optimize Ocular Oncology Drug Delivery
July 09, 2019 07:05 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., July 09, 2019 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for...
Clearside Biomedical to Present at the JMP Securities Life Sciences Conference
June 11, 2019 07:05 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., June 11, 2019 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for...
Clearside Biomedical to Present at the UBS Global Healthcare Conference
May 15, 2019 07:05 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., May 15, 2019 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for...
Clearside Biomedical Announces First Quarter 2019 Financial Results and Provides Corporate Update
May 08, 2019 07:05 ET
|
Clearside Biomedical, Inc.
- Scientific Presentations Support Broad Applicability of Clearside Delivery Platform - - XIPERE™ under review for October 19, 2019 PDUFA Date -- Management to Host Webcast and Conference Call Today...
Clearside Biomedical’s Suprachoroidal Space Injection Platform Featured at Multiple Ophthalmology and Gene Therapy Medical Meetings
May 01, 2019 07:05 ET
|
Clearside Biomedical, Inc.
- SCS injection platform continues to be well-received by the medical community - - Suprachoroidal administration may offer targeted delivery of gene therapies without risks of vitrectomy and...
Clearside Biomedical to Report First Quarter 2019 Financial Results and Provide Corporate Update on Wednesday, May 8, 2019
April 25, 2019 07:05 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., April 25, 2019 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for...
Clearside Biomedical Announces Multiple Presentations on its Suprachoroidal Space® Injection Platform at Upcoming Medical Meetings
April 18, 2019 07:05 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., April 18, 2019 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for...
Clearside Biomedical Appoints Dr. George Lasezkay as Interim CEO
April 08, 2019 07:05 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., April 08, 2019 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for...
Clearside Biomedical to Present at the 18th Annual Needham Healthcare Conference
April 02, 2019 16:05 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., April 02, 2019 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for...